Alliance Wealth Advisors LLC UT Raises Holdings in Boston Scientific Corporation $BSX

Alliance Wealth Advisors LLC UT increased its position in Boston Scientific Corporation (NYSE:BSX) by 207.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 16,560 shares of the medical equipment provider’s stock after purchasing an additional 11,178 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Boston Scientific were worth $1,617,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. State Street Corp boosted its stake in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Geode Capital Management LLC boosted its stake in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares during the period. Norges Bank acquired a new position in Boston Scientific in the second quarter valued at $2,089,937,000. Finally, Invesco Ltd. raised its holdings in shares of Boston Scientific by 1.4% in the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after buying an additional 226,578 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 1.6%

Shares of BSX opened at $74.54 on Friday. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50. The stock has a 50-day moving average price of $89.23 and a 200 day moving average price of $96.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.96 and a current ratio of 1.62. The company has a market capitalization of $110.61 billion, a P/E ratio of 38.42, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the company posted $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BSX shares. Evercore lowered their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Barclays lowered their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Robert W. Baird reduced their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. JPMorgan Chase & Co. lowered their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, Morgan Stanley cut their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.